Specimen:
Collect
- One SST
Also Acceptable:
- One Green Top (Li Heparin)
- One Lavender (EDTA)
- One Pink Top (EDTA)
- One Red Top
Submit
- 1 mL (Min:0.5 mL) Serum . Submit Refrigerated. Submit in a Standard Transport Tube.
Also Acceptable:
- 1 mL (Min:0.5 mL) Plasma . Submit Refrigerated. Submit in a Standard Transport Tube.
Special Handling
- Allow specimen to clot completely at room temperature
- Avoid Repeated Freeze/Thaw Cycles
- For patients receiving therapy with high biotin doses (>5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
- Minimize air exposure
- Separate from cells ASAP
- For Medicare Patients only with screening DX.
Stability
Ambient: 2 Hour(s); Refrigerated: 5 Day(s); Frozen: 6 Month(s); Incubated: Unacceptable
Methodology
- Electrochemiluminescence Immunoassay (ECLIA)
Performed
Mon-Fri
Reported
1-3 Day(s)
CPT Codes
- G0103
Interpretive Data
General Reference Range : 0.000-4.000 ng/mL
The Roche PSA electrochemiluminescent immunoassay is the test methodology used. Results obtained with different assay methods or kits cannot be used interchangeably. The Roche PSA method is approved for use as an aid in the detection of prostate cancer when used in conjunction with a digital rectal exam in men age 50 and older. The Roche PSA is also indicated for the serial measurement of PSA to aid in the management of cancer patients. Elevated concentrations of PSA in serum are generally indicative of a pathologic condition of the prostate (prostatitis, benign hyperplasia or carcinoma).
Biotin in specimens taken from patients on high-dose biotin therapy or supplements may interfere with this test and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
The Roche PSA electrochemiluminescent immunoassay is the test methodology used. Results obtained with different assay methods or kits cannot be used interchangeably. The Roche PSA method is approved for use as an aid in the detection of prostate cancer when used in conjunction with a digital rectal exam in men age 50 and older. The Roche PSA is also indicated for the serial measurement of PSA to aid in the management of cancer patients. Elevated concentrations of PSA in serum are generally indicative of a pathologic condition of the prostate (prostatitis, benign hyperplasia or carcinoma).
Biotin in specimens taken from patients on high-dose biotin therapy or supplements may interfere with this test and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
Components
- 2293 - PSA, MC SCREENING
Last Updated: May 11, 2025 @ 9:13 am
Disclaimer:
It is preferable to locate tests on the website and not rely on printed test information, which may soon be out of date. Updated test information can only be guaranteed by using this website.
